As someone who’s spent years guiding families and business owners through the changing landscape of health insurance, I see firsthand how new therapies—like the rapidly growing GLP-1 drugs—are shifting the conversation. These medications are making waves for both diabetes and obesity, but their widespread use is causing pharmacy costs to climb. That’s why insurers are tightening coverage for obesity treatments, while diabetes coverage remains steady. The big question going forward is whether future coverage will hinge on stronger clinical evidence, pricing, and the true value these therapies provide—especially with so much still unknown about their long-term benefits. For anyone relying on health insurance to support lasting well-being, these decisions matter. It’s a reminder of why thoughtful planning and staying informed are so important.
Leave a Reply